Our Approach

Qualigen is a biotechnology company focused on the development and commercialization of therapeutic products for the treatment of cancer and viral diseases, as well as expansion of its flagship FastPack®

diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.

More About Us

Our Therapeutics Pipeline

Our therapeutics pipeline includes anti-viral compounds such as QN-165 (formerly referred to as AS1411), cancer drug compounds such as QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device.

Select a Drug Candidate to Learn More

ProgramDiscoveryPreclinicalPhase 1Phase 2
QN-165
COVID-19
QN-247
AML
RAS-F
STARS™
IndicationStage
QN-165 Phase 1
QN-247 Preclinical
RAS-F Preclinical
STARS™ Discovery
QN-165QN-247RAS-FSTARS™Program
Discovery
Preclinical
Phase 1
Phase 2